Susan Collins actually said...
If it is a short enough time, it is not going to be worth the amount of money that the manufacturer--well, they are not manufacturers; they are more like what I would call hedge fund pharmaceutical companies--would pay to get the rights to that drug.
Context
Discussing the impact of expedited drug approvals on pharmaceutical companies' pricing strategies.
01/27/2016